This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Acupuncture for Chemotherapy-induced Peripheral Neuropathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by Pusan National University Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Pusan National University Hospital Identifier:
First received: June 18, 2013
Last updated: July 16, 2013
Last verified: July 2013
The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.

Condition Intervention
Peripheral Neuropathy Toxicity Due to Chemotherapy Lymphoma Multiple Myeloma Procedure: Acupuncture

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study

Resource links provided by NLM:

Further study details as provided by Pusan National University Hospital:

Primary Outcome Measures:
  • Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline [ Time Frame: At baseline, 1, 2, 3, and 7 wks from baseline ]

Secondary Outcome Measures:
  • Change of VAS (Visual Analogue Scale) from baseline [ Time Frame: At baseline, 1, 2, 3, and 7 wks from baseline ]
  • Change of FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity) from baseline [ Time Frame: At baseline, 1, 2, 3, and 7 wks from baseline ]
  • Adverse events [ Time Frame: From study enrollment to the last follow-up (up to 7 wks) ]

Estimated Enrollment: 36
Study Start Date: June 2013
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acupuncture
Acupuncture treatment
Procedure: Acupuncture
Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
No Intervention: Control
No other active treatment or sham acupuncture for this symptoms


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma.
  • Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta and/or Lyrica. Patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period.
  • Patients, or the legal guardians of patients, must have the ability to understand Korean, and be ble to provide informed consent.
  • ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2.
  • If the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception.

Exclusion Criteria:

  • Other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and HIV.
  • Current active treatment for lymphoma or multiple myeloma
  • Ongoing local infection at or near the acupuncture point adopted in this trial.
  • Severe immunocompromised patients, leukopenia ( < 4,000/㎣) or neutropenia ( < 1,500/㎣)
  • Known coagulopathy, thrombocytopenia (< 50,000/㎣), and taking heparin (including low molecular weight heparin) or Coumadin at any dose.
  • Serious emotional or mental problems that precludes study entry.
  • Mental and physical disability that precludes accurate acupuncture.
  • Serious systemic diseases such as active infection, severe heart disease, uncontrolled hypertension and diabetes mellitus.
  • Cardiac pacemaker.
  • Pregnant or breastfeeding
  • Acupuncture therapy within the previous 30 days
  • Concurrent other complementary and alternative therapy such as herbal agents, high dose vitamins, and etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01892852

Contact: Chang Woo Han, PhD +82-51-240-6835

Korea, Republic of
Department of Hematology-Oncology and Center for Integrative Medicine, Pusan National University Hospital Recruiting
Busan, Korea, Republic of, 602-739
Contact: Chang Woo Han, PhD    +82-51-240-6835   
Principal Investigator: Ho-Jin Shin, MD, PhD         
Sub-Investigator: Chang Woo Han, PhD         
Sub-Investigator: Eui-Hyoung Hwang, PhD         
Sponsors and Collaborators
Pusan National University Hospital
Principal Investigator: Ho-Jin Shin, PhD Pusan National University Hospital
  More Information

Responsible Party: Pusan National University Hospital Identifier: NCT01892852     History of Changes
Other Study ID Numbers: AcuCIPN
Study First Received: June 18, 2013
Last Updated: July 16, 2013

Keywords provided by Pusan National University Hospital:
Traditional Korean Medicine

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Peripheral Nervous System Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Neuromuscular Diseases
Nervous System Diseases processed this record on July 27, 2017